Industrial-Scale Synthesis of Intrinsically Radiolabeled 64CuS Nanoparticles for Use in Positron Emission Tomography (PET) Imaging of Cancer

详细信息    查看全文

• 作者：Rubel Chakravarty ; Sudipta Chakraborty ; Raghumani Singh Ningthoujam ; K. V. Vimalnath Nair ; K. Shitaljit Sharma ; Anand Ballal ; Apurav Guleria ; Amit Kunwar ; Haladhar Dev Sarma ; Rajesh Kumar Vatsa ; Ashutosh Dash
• 刊名：Industrial & Engineering Chemistry Research
• 出版年：2016
• 出版时间：December 7, 2016
• 年：2016
• 卷：55
• 期：48
• 页码：12407-12419
• 全文大小：841K
• ISSN：1520-5045

文摘

Synthesis of intrinsically radiolabeled nanoparticles is an emerging concept in cancer theranostics and is expected to play an imperative role in translating nanotechnology research into the nuclear medicine industry. In order to reduce reliance on cyclotron produced ⁶⁴Cu (t_1/2 = 12.7 h, EC 45%, β⁺ 17.9%, β^– 37.1%) and increase global accessibility of this radioisotope for preclinical and clinical investigations, we have explored the feasibility of using neutron-activated ⁶⁴Cu produced in research reactors for potential use in cancer theranostics. A viable strategy has been developed for production of ⁶⁴Cu in medium-flux research reactors and its utilization toward industrial-scale (GBq level) synthesis of intrinsically radiolabeled ⁶⁴CuS nanoparticles (∼30 nm particle size). The synthesis procedure was easily executable in a hot cell equipped with remotely operable gadgets and ⁶⁴CuS nanoparticles could be synthesized in a form suitable for clinical administration. The stability of the nanoparticles under physiological conditions was established by detailed in vitro studies in phosphate buffered saline (PBS) and mouse serum media. The biological efficacy of intrinsically radiolabeled ⁶⁴CuS nanoparticles was studied in C57BL/6 mice bearing melanoma tumors. The results of the biodistribution studies revealed significant tumor uptake (4.64% ± 1.71%ID/g) within 4 h post-injection (where %ID is the percent injected radioactivity dose), with good tumor-to-background contrast. Collectively, the promising results obtained in this study suggest that the concept of intrinsically radiolabeled nanoplatforms can be employed to facilitate widespread utilization of neutron-activated ⁶⁴Cu in nuclear medicine industry.